3-Thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one | 1465270-08-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
• CAS: 1465270-08-9
• 化学式: C₁₆H₁₆O₄S
• 分子量: 304.367
• InChiKey: BWGAMTYKVBCHPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  73
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-Thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 在 二氧化硫脲 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 异丙醇 为溶剂， 生成 ethyl 3-(thiophen-2-yl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  [EN] 2,3,5 TRISUBSTITUTED PYRROLE DERIVATIVES AS TOPOISOMERASE INHIBITORS AND THERAPEUTIC USES THEREOF
  [FR] DÉRIVÉS TRISUBSTITUÉS 2, 3, 5 DE PYRROLE EN TANT QU'INHIBITEURS DE TOPOISOMÉRASE ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  具有拓扑异构酶抑制作用的Formula（1）化合物包括[在此插入公式]其中，R1从以下组中选择：H，OR5，可选择取代的C1-C12烷基，卤代烷基，C2-C12烯基，C2-C12炔基，C1-C12烷氧基，C1-C12卤代烷氧基，C2-C10杂基烷基，C3-C12环烷基，C3-C12环烯基，C2-C12杂环烷基，C2-C2杂环烯基，C6-C18芳基和C1-C18杂芳基；R2、R3和R4分别从以下组中选择：H，卤素，CN，-NO2，SH，CF3，OH，CO2H，CONH2，OCF3，可选择取代的C1-C12烷基，可选择取代的C1-C12卤代烷基，可选择取代的C2-C12烯基，可选择取代的C2-C12炔基，可选择取代的C1-C12烷氧基，可选择取代的C1-C12卤代烷氧基，可选择取代的C2-C12杂基烷基，可选择取代的C3-C12环烷基，可选择取代的C3-C12环烯基，可选择取代的C2-C12杂环烷基，可选择取代的C2-C12杂环烯基，可选择取代的C6-C18芳基，可选择取代的C1-C18杂芳基；R5选择为H，可选择取代的C1-C12烷基，可选择取代的C2-C12烯基，可选择取代的可选择取代的C1-C12卤代烷基，可选择取代的C3-C12环烷基，可选择取代的C6-C18芳基，可选择取代的C1-Ci18杂芳基；或其药学上可接受的盐、N-氧化物或前药。

  公开号：

  WO2017029684A1
• 作为产物：
  描述：

  2-乙酰基噻吩 、 3,4,5-三甲氧基苯甲醛 在 硫酸 、 溶剂黄146 作用下， 反应 3.0h， 生成 3-Thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  Anti-proliferative potential of triphenyl substituted pyrimidines against MDA-MB-231, HCT-116 and HT-29 cancer cell lines

  摘要：

  A series of triphenyl substituted pyrimidines as analogous of colchicine and combretastatin A-4 was synthesized and evaluated for the antiproliferative potential. The compounds were screened against MDA-MB-231, HCT-116 and HT-29 cell lines using MTT assay. Most of the compounds displayed antiproliferative activity in low to sub micro molar concentration. Amongst the synthesized derivatives, compounds HK-2, HK-10 and HK-13 were found to be effective against all the three cancer cell lines. HK-2 exhibited IC50 values of 3.39 mu M, 4.78 mu M and 4.23 mu M, HK-10 showed IC50 values of 0.81 mu M, 5.89 mu M, 4.96 mu M and HK-13 showed IC50 values 3.24 mu M, 4.93 mu M and 4.73 mu M against MDA-MB-231, HCT-116 and HT-29 cancer cell lines, respectively. HK-10 was found to be the most potent compound in the series with IC50 values of 0.81 mu M against MDA-MB-231. In the cell cycle analysis, HK-2 and HK-10 showed cell arrest at G2/M phase of the cell cycle while HK-13 inhibited cell growth at the G1/G0 phase. All the three compounds showed cell death induced through apoptosis. In the docking studies, HK-2, HK-10 and HK-13 were found to fit well in the colchicine binding site of the tubulin. Some of the compounds in the current series were found to be promising against all the three cancer cell lines and may act as potent leads for further development.

  DOI：

  10.1016/j.bmcl.2020.127468

文献信息

• Design, synthesis, biological evaluation of 3,5-diaryl-4,5-dihydro-1H-pyrazole carbaldehydes as non-purine xanthine oxidase inhibitors: Tracing the anticancer mechanism via xanthine oxidase inhibition
  作者：Gaurav Joshi、Manisha Sharma、Sourav Kalra、Navnath S. Gavande、Sandeep Singh、Raj Kumar

  DOI：10.1016/j.bioorg.2020.104620

  日期：2021.2

  (2a-2x) as xanthine oxidase inhibitors (XOIs). A docking model was developed for the prediction of XO inhibitory activity of our novel compounds. Furthermore, our compounds anticancer activity results in low XO expression and XO-harboring cancer cells both in 2D and 3D-culture models are presented and discussed. Among the array of synthesized compounds, 2b and 2m emerged as potent XO inhibitors having

  黄嘌呤氧化酶 (XO) 主要用于开发抗高尿酸血症/抗痛风剂，因为它催化黄嘌呤和次黄嘌呤转化为尿酸。由于催化过程中活性氧 (ROS) 的产生和致癌物质的代谢活化，XO 在各种癌症中的过度表达非常相关。在此，我们报告了一系列 3,5-二芳基-4,5-二氢-1 H-吡唑甲醛衍生物 ( 2a - 2x) 作为黄嘌呤氧化酶抑制剂 (XOI)。开发了一种对接模型，用于预测我们的新型化合物的 XO 抑制活性。此外，我们的化合物抗癌活性导致 2D 和 3D 培养模型中的低 XO 表达和 XO 携带癌细胞。合成的化合物的阵列中，图2b和2米成为具有IC强效抑制剂XO 50值分别为 9.32 ± 0.45 µM 和 10.03 ± 0.43 µM。这两种化合物均诱导细胞凋亡，在 G1 期停止细胞周期进程，提高 ROS 水平，改变线粒体膜电位，并抑制抗氧化酶。由于我们的化合物诱导的氧化应激增加，细胞中 miRNA
• One-pot synthesis of multifunctionalized m-terphenyls
  作者：Meng-Yang Chang、Chieh-Kai Chan、Shin-Ying Lin、Ming-Hao Wu

  DOI：10.1016/j.tet.2013.09.036

  日期：2013.11

  one-step synthetic protocol toward multifunctionalized m-terphenyls 5 and sulfonyl m-terphenyls 6 is developed from substituted chalcones 1 and allyl sulfone 2 in good yields via a [3C+3C] annulation. The NaH-mediated annulation features transition metal catalyst-free condition. Chalcones 1 with the functional groups tolerance are easily prepared via Claisen–Schmidt condensation of substituted benzaldehydes

  朝向多官能化一种简便一步法合成的协议米-terphenyls 5和磺酰米-terphenyls 6选自取代的查耳酮开发1和烯丙基砜2经由[3C + 3C]环以良好的收率。NaH介导的环化反应具有无过渡金属的条件。查耳酮1与官能团耐受性很容易通过取代的苯甲醛的克莱森-施密特缩合制备3与苯乙酮4以定性收率下含水碱性甲醇溶液。
• One-pot synthesis of multisubstituted quaterphenyls and cyclopropanes
  作者：Meng-Yang Chang、Chieh-Kai Chan、Shin-Ying Lin、Ming-Hao Wu

  DOI：10.1016/j.tet.2013.09.060

  日期：2013.11

  quaterphenyls 3 or cyclopropanes 4 is developed from substituted chalcones 1 and sulfones 2 in good yields via a regioselective [3C+3C] or [1C+2C] annulation. The reaction features mild conditions, multisubstitution, and functional groups tolerance and is transition metal catalyst-free. The protocol provides a novel alternative to the conventional methodologies for the synthesis of quaterphenyls or

  朝向多官能化quaterphenyls一种有效的一步合成路线3或环丙烷4选自取代的查耳酮开发1和砜2以良好的收率通过区域选择性[3C + 3C]或[1C + 2C]环。该反应具有温和的条件，多取代和对官能团的耐受性，并且不含过渡金属催化剂。该方案为合成四苯基或环丙烷的常规方法提供了一种新颖的替代方法。
• One‐Pot Construction of Sulfonyl Benzonorcaradienes
  作者：Meng‐Yang Chang、Chun‐Yi Lin

  DOI：10.1002/adsc.202300012

  日期：2023.3.21

  We report here on a one-pot stereoselective synthesis of strained sulfonyl benzonorcaradienes, which proceeds through base-mediated tandem annulation of o-bis-sulfonylmethyl arenes with diversified chalcones (α,β-unsaturated carbonyls) via intermolecular desulfonylative cyclopropanation, followed by intramolecular condensation. A plausible mechanism is proposed and discussed. The proposed synthetic

  我们在这里报告了应变磺酰基苯并碳二烯的一锅法立体选择性合成，它通过碱介导的o -双磺酰甲基芳烃与多种查耳酮（α,β-不饱和羰基）的串联环化通过分子间脱磺酰化环丙烷化反应进行，然后进行分子内缩合. 提出并讨论了一种合理的机制。拟议的合成路线形成两个碳-碳单 (CC) 键和一个碳-碳双 (C=C) 键。
• [EN] 2,3,5 TRISUBSTITUTED PYRROLE DERIVATIVES AS TOPOISOMERASE INHIBITORS AND THERAPEUTIC USES THEREOF<br/>[FR] DÉRIVÉS TRISUBSTITUÉS 2, 3, 5 DE PYRROLE EN TANT QU'INHIBITEURS DE TOPOISOMÉRASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：UNIV OF MYSORE

  公开号：WO2017029684A1

  公开（公告）日：2017-02-23

  The compounds of Formula (1) having topoisomerase inhibitory effect includes [Formula should be inserted here] wherein, R1 is selected from a group consisting of H, OR5, optionally substituted C1-C12 alkyl, haloalkyl, C2-C12alkenyl, C2-C12alkynyl, C1-C12alkyloxy, C1-C12haloalkyloxy, C2-C10 heteroalkyl, C3- C12 cycloalkyl, C3-C12cycloalkenyl, C2- C12heterocycloalkyl, C2-C2 heterocycloalkenyl, C6-C18aryl, and C1-C18heteroaryl; R2, R3 and R4 are independently selected from a group consisting of H, halogen, CN, - NO2, SH, CF3, OH, CO2H, CONH2, OCF3, optionally substituted C1-C12alkyl, optionally substituted C1-C12haloalkyl optionally substituted C2-C12alkenyl, optionally substituted C2- C12alkynyl, optionally substituted C1-C12alkyloxy, optionally substituted C1- C12haloalkyloxy, optionally substituted C2-C12heteroalkyl, optionally substituted C3- C12cycloalkyl, optionally substituted C3-C12 cycloalkenyl, optionally substituted C2-C12 heterocycloalkyl, optionally substituted C2-C12 heterocycloalkenyl, optionally substituted C6- C18aryl, and optionally substituted C1-C18heteroaryl; R5 is selected H, optionally substituted C1-C12alkyl, optionally substituted C2- C12alkenyl, optionally substituted optionally substituted C1-C12 haloalkyl, optionally substituted C3-C12cycloalkyl, optionally substituted C6- C18aryl, and optionally substituted C1- Ci18heteroaryl; or a pharmaceutically acceptable salt, N-oxide, or prodrug thereof.

  具有拓扑异构酶抑制作用的Formula（1）化合物包括[在此插入公式]其中，R1从以下组中选择：H，OR5，可选择取代的C1-C12烷基，卤代烷基，C2-C12烯基，C2-C12炔基，C1-C12烷氧基，C1-C12卤代烷氧基，C2-C10杂基烷基，C3-C12环烷基，C3-C12环烯基，C2-C12杂环烷基，C2-C2杂环烯基，C6-C18芳基和C1-C18杂芳基；R2、R3和R4分别从以下组中选择：H，卤素，CN，-NO2，SH，CF3，OH，CO2H，CONH2，OCF3，可选择取代的C1-C12烷基，可选择取代的C1-C12卤代烷基，可选择取代的C2-C12烯基，可选择取代的C2-C12炔基，可选择取代的C1-C12烷氧基，可选择取代的C1-C12卤代烷氧基，可选择取代的C2-C12杂基烷基，可选择取代的C3-C12环烷基，可选择取代的C3-C12环烯基，可选择取代的C2-C12杂环烷基，可选择取代的C2-C12杂环烯基，可选择取代的C6-C18芳基，可选择取代的C1-C18杂芳基；R5选择为H，可选择取代的C1-C12烷基，可选择取代的C2-C12烯基，可选择取代的可选择取代的C1-C12卤代烷基，可选择取代的C3-C12环烷基，可选择取代的C6-C18芳基，可选择取代的C1-Ci18杂芳基；或其药学上可接受的盐、N-氧化物或前药。